JL-1

Cat.No.: CSC-C2542

Species: Homo sapiens (Human)

Source: Lung

Morphology: adherent, epithelial-like cells growing in monolayers

Culture Properties: monolayer

Inquire for Price

Specification
Background
Scientific Data
Q & A
Customer Review

Cat.No.

CSC-C2542

Description

Established from the untreated malignant epithelioid mesothelioma of the pleura of a 54-year-old man with asbestos cancer in 2003

Species

Homo sapiens (Human)

Source

Lung

Recommended Medium

80% DMEM or NCTC-109 + 20% h.i.FBS + 2 mM L-glutamine

Culture Properties

monolayer

Morphology

adherent, epithelial-like cells growing in monolayers

Karyotype

Human flat-moded karyotype with 12 % polyploidy; 42-47<2n>XY, +5, +7, -10, -13, +20, der(1)t(1;15)(q11;q11), inv(3)(p1?q2?), der(5)t(5;16)(q11;?), add(10)(q25), der(11)t(10;11)(q21;q23), der(14)t(1;14)(q11;q31); sdl with add(9)(p11), del(16)(q11); karyoty

Disease

Pleural Epithelioid Mesothelioma

Quality Control

Mycoplasma: negative in microbiological culture, PCR assays
Immunology: cytokeratin +, cytokeratin-7 +, cytokeratin-8 +, cytokeratin-17 -, cytokeratin-18 +, cytokeratin-19 +, desmin -, endothel -, GFAP -, neurofilament -, vimentin +
Viruses: PCR: EBV -,

Storage and Shipping

Frozen with 70% medium, 20% FBS, 10% DMSO at about 1.5 x 10^6 cells/ampoule; ship in dry ice; store in liquid nitrogen

Synonyms

JL1

Citation Guidance

If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

JL-1 is a human-derived continuous cell line originally established from malignant mesothelioma-associated tissue. It is a tumorigenic, adherent cell model that exhibits mixed epithelial- and spindle-like morphology, reflecting the heterogeneity commonly observed in mesothelial-derived malignancies. JL-1 cells display robust proliferative capacity and are widely utilized as an in vitro system for studying the biological behavior of aggressive mesothelioma and related tumor types.

At the molecular level, JL-1 cells retain key characteristics of malignant mesothelial cells and are frequently used in research focusing on cytoskeletal organization, cell adhesion, migration, and invasion. Their stable growth properties and reproducible phenotypic features make them suitable for mechanistic studies investigating tumor progression, epithelial-mesenchymal transition (EMT)-like processes, and tumor microenvironment interactions. In addition, JL-1 cells have been applied in transcriptomic and functional genomic studies to identify dysregulated signaling pathways involved in tumorigenesis.

JL-1 is also used as a model for anticancer drug screening and therapeutic response evaluation, particularly in studies targeting cell motility and survival pathways. Due to its consistent performance in vitro and relevance to mesothelioma biology, JL-1 serves as a valuable experimental platform for both basic research and translational oncology applications, supporting the development of novel therapeutic strategies against highly invasive thoracic tumors.

Pirfenidone Inhibits Mesothelioma Cell Proliferation and Migration

Malignant mesothelioma is an aggressive cancer characterized by a desmoplastic stroma and chemoresistance. Li's team evaluated the anti-tumor potential of pirfenidone, an anti-fibrotic agent. Pirfenidone significantly reduced the proliferation of human (JL-1, H2052, JP5) and mouse (AB12) mesothelioma cell lines after 48 hours (Fig. 1A). A concentration of 750 μg/ml reduced H2052 cell growth by _{50%, while other cell lines showed}70% inhibition. Combining pirfenidone with 10 μM cisplatin-the standard chemotherapeutic backbone-resulted in at least an additive reduction in proliferation for JL-1 and H2052 cells (Fig. 1B, C); however, no synergistic effect was observed when combining pirfenidone with pemetrexed.

Beyond proliferation, pirfenidone inhibited cell motility. Transwell assays demonstrated a concentration-dependent reduction in JL-1 and H2052 cell migration and invasion through collagen I-coated inserts (Fig. 2A, B). Furthermore, pirfenidone suppressed the invasive sprouting of H2052 cells in 3D Matrigel (Fig. 2C) and reduced the invasive growth of JL-1 cells in a 3D collagen matrix (Fig. 2D). These findings identify pirfenidone as a novel inhibitor of both proliferation and migration in malignant mesothelioma.